To define the cell populations that drive joint inflammation in rheumatoid arthritis (RA),
R
A is an autoimmune disease with chronic inflammation in the synovium of the joint tissue [1] [2] [3] . This inflammation leads to joint destruction, disability, and shortened life span 4 . Defining key cellular subsets and their activation states in the inflamed tissue is a critical step in defining new therapeutic targets for RA. CD4 + T cells 5, 6 , B cells 7 , monocytes 8, 9 , and fibroblasts 10, 11 have established relevance to RA pathogenesis. Here, we use single-cell technologies to view all of these cell types simultaneously across a large collection
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ResouRce Nature ImmuNology of samples from inflamed joints. We believe a global single-cell portrait of how different cell types work together would help identify new pathways in RA and eventually new therapeutics.
Application of transcriptomic and cellular profiling technologies to whole synovial tissue has already identified specific cell populations associated with RA 3, [12] [13] [14] . However, most studies have focused on a preselected cell type, surveyed whole tissues rather than disaggregated cells, or used only a single technology platform. The latest advances in single-cell technologies offer an opportunity to identify disease-associated cell subsets in human tissues at high resolution in an unbiased fashion [15] [16] [17] . These technologies have already been used to discover roles for T peripheral helper (T PH ) cells 18 and HLA-DR + CD27 -cytotoxic T cells 19 in RA pathogenesis. Studies using scRNA-seq have defined myeloid cell heterogeneity in human blood 20 and identified overabundance of PDPN + CD34 − THY1 + (THY1, also known as CD90) fibroblasts in RA synovial tissue 15, 21 . To generate high-dimensional multimodal single-cell data from synovial tissue samples collected across a collaborative network of research sites, we developed a robust pipeline 22 in the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) consortium. We collected and disaggregated tissue samples from patients with RA and OA and then subjected constituent cells to scRNA-seq, sorted-population bulk RNA-seq, mass cytometry, and flow cytometry. We developed a unique computational strategy based on canonical correlation analysis (CCA) to integrate multimodal transcriptomic and proteomic profiles at the single-cell level. A unified analysis of single cells across data modalities can precisely define contributions of specific cell subsets to pathways relevant to RA and chronic inflammation.
Results
Generation of parallel mass cytometric and transcriptomic data from synovial tissue. In phase 1 of AMP RA/SLE, we recruited 36 patients with RA who met the 1987 American College of Rheumatology (ACR) classification criteria and 15 patients with OA from ten clinical sites over 16 months (Supplementary Table 1) and obtained synovial tissues from ultrasound-guided biopsies or joint replacements (Methods and Fig. 1a) . We required that all tissue samples included had synovial lining documented by means of histology. Synovial tissue disaggregation yielded an abundance of viable cells for downstream analyses (362,190 ± 7,687 (mean ± s.e.m.) cells per tissue). We used our validated strategy for cell sorting 22 ( Fig. 1a) Fig. 1a ). We applied bulk RNA-seq to all four sorted subsets for all 51 samples. For samples with sufficient cell yield (Methods), we also measured single-cell protein expression using a 34-marker mass cytometry panel (n = 26; Supplementary Table 2 ) and single-cell RNA expression in sorted cell populations (n = 21; Fig. 1b ).
Summary of computational data integration strategy to define cell populations. To confidently define RA-associated cell populations, we integrated multiple data modalities (Fig. 1b,c) . We used bulk RNA-seq data as the reference point, because these data were available for almost all the donors for all the cell types, had the highest dimensionality, and were least sensitive to technical artifacts (Fig. 1b) .
Integrating scRNA-seq with bulk RNA-seq data ensures robust discovery of cell populations. Here, we used CCA to find linear combinations of bulk RNA-seq samples and scRNA-seq cells (Fig. 1c,d ) to create gene expression profiles that were maximally correlated. These linear combinations captured sources of shared variation between the two datasets and allowed us to identify individual cell populations that drive variation in the bulk RNA-seq data. We analyzed the scRNA-seq data by using the canonical variate coefficients for each cell to compute a nearest neighbor network, identifying clusters with a community detection algorithm, and evaluating the separation between clusters with Silhouette analysis (Methods and Supplementary Fig. 2b ).
We identified cell clusters in mass cytometry data using densitybased clustering 23 . Next, we used CCA to identify linear combinations of bulk RNA-seq genes and mass cytometry cluster abundances that maximized correlation across patients. These canonical variates offered a way to visualize genes and mass cytometry clusters together. We then queried this CCA result with the best marker genes from scRNA-seq to establish a relationship between each scRNA-seq cluster and each mass cytometry cluster (Methods). We also used CCA to associate bulk gene expression in each sample with proportions of cells in different flow cytometry gates.
Flow cytometry features define a set of RA synovia that are leukocyte rich. Histology of RA synovial tissues revealed heterogeneous tissue composition with variable lymphocyte and monocyte infiltration (Fig. 2a,b and Supplementary Fig. 2c,d ). This heterogeneity was expected, because variation in tissue immune cell infiltration reflects local disease activity in the source joint. Consequently, we employed a data-driven approach to separate samples on the basis of flow cytometry of lymphocyte and monocyte infiltration in each tissue sample ( Supplementary Fig. 1b,c) . We calculated a multivariate normal distribution of these parameters based on OA samples as a reference, and for each RA sample, we calculated the Mahalanobis distance from OA 24 . We defined the maximum OA distance (4.5) as the threshold for defining leukocyte-rich RA (>4.5, n = 19) or leukocyte-poor RA (<4.5, n = 17) samples (Methods and Supplementary Fig. 1d ). Whereas leukocyte-rich RA tissues had substantial infiltration of synovial T cells and B cells, leukocytepoor RA tissues had cellular compositions more similar to those of OA samples (Fig. 2c ). Synovial monocyte abundances were similar between RA and OA samples (Fig. 2c) .
To test whether our classification indicated inflammation, we assessed tissue histology and assigned each sample a Krenn inflammation score 25 . Samples that we classified as leukocyte-rich RA had significantly higher Krenn inflammation scores than those of leukocyte-poor RA or OA samples (Fig. 2d) . In contrast, synovial lining membrane hyperplasia was not significantly different between leukocyte-rich RA, leukocyte-poor RA, and OA samples (Fig. 2d) . We observed significant correlation between synovial leukocyte infiltration, as measured via flow cytometry and the histological Krenn inflammation score (Fig. 2e) . Mass cytometry in 26 synovial tissues was consistent with flow cytometry and histology. OA and leukocyte-poor RA samples were characterized by a high abundance of fibroblasts and endothelial cells; whereas, leukocyte-rich RA tissues were characterized by a high abundance of CD4 + T cells, CD8
+ T cells, and B cells ( Fig. 2f and Supplementary Fig. 3a ).
Single-cell RNA-seq analysis reveals distinct cell subpopulations. Next, we analyzed 5,265 scRNA-seq profiles passing quality control (Methods), including 1,142 B cells, 1,844 fibroblasts, 750 monocytes, and 1,529 T cells. We used canonical variates (from CCA with bulk RNA-seq) to define 18 cell clusters that were independent of donor (n = 21) and technical plate effects (n = 24) (Fig. 3a,b and Supplementary Figs. 2c and Fig. 4a ). In contrast, conventional principal component analysis (PCA)-based clustering led to clusters that were confounded by batch effects (Supplementary Fig. 4b ). All of the clusters in the PCA-based clustering, excluding clusters confounded by batch, were identified in CCA-based clustering. Next, we compared expression values between cells in the cluster and all other cells to select cluster marker genes (Methods and Supplementary + lining fibroblasts (SC-F4). In monocytes (Fig. 3d) , we identified IL1B + pro-inflammatory monocytes (SC-M1), NUPR1
+ monocytes (SC-M2), C1QA + monocytes (SC-M3), and interferon (IFN) activated monocytes (SC-M4). In T cells (Fig. 3e) 
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+ memory B cells (SC-B2). We identified an autoimmune-associated B cell (ABC) cluster (SC-B3) with high expression of ITGAX (also known as CD11c) and a plasmablast cluster (SC-B4) with high expression of immunoglobulin genes and XBP1, a transcription factor for plasma cell differentiation 27 . We assessed protein fluorescence measurements of typical cell type markers, which were consistent with our identified scRNA-seq clusters ( Supplementary Fig. 2e ). Cell density quantified from ten histology samples correlated with the lymphocyte flow cytometric cell yields, suggesting that samples with the most single-cell measurements were those with the best yields and the most inflammation ( Supplementary Fig. 5 ).
Distinct synovial fibroblasts defined by cytokine activation and MHC II expression. To identify the fibroblast subpopulations that are overabundant in leukocyte-rich RA synovia, we selected marker genes for each cluster and assessed their expression levels in bulk RNA-seq from sorted fibroblasts (CD45 − PDPN + ) of samples from patients with RA and OA. For example, genes associated with HLA-DRA hi (SC-F2) fibroblasts were more highly expressed in bulk RNA-seq samples from leukocyte-rich RA than in OA samples (t test P < 1 × 10 −3 for HLA-DRA, IFI30, and IL6) (Fig. 4a) . Because the expression profile of a bulk tissue sample is an aggregate of the expression profiles of its constituent cell populations, this result suggests expansion of HLA-DRA hi (SC-F2) fibroblasts in RA tissues. Genes associated with CD55 + fibroblasts (SC-F4) were significantly more highly expressed in bulk RNA-seq samples from OA than in those from leukocyte-rich RA (t test P < 1 × 10 −3 for HBEGF, CLIC5, HTRA4, and DNASE1L3) (Fig. 4a) . CD55 + fibroblasts (SC-F4) were the most transcriptionally distinct subset from the three THY1 + clusters (SC-F1-3), including the highest expression of lubricin (PRG4), suggesting that these cells represent synovial lining fibroblasts and THY1 + fibroblasts (SC-F1-3) represent sublining (Fig. 4a) . Next, we use the averaged expression level of the best marker genes for each scRNA-seq cluster (AUC > 0.7) and tested for differential expression in bulk RNA-seq fibroblast samples from leukocyte-rich RA and OA synovia. ). We profiled these cells with mass cytometry, flow cytometry, sorted low-input bulk RNA-seq, and single-cell RNA-seq (joint image from Servier Medical Art). b, Presence and absence of five different data types for each tissue sample after stringent quality control. c, Schematic of each dataset and the shared dimensions used to analyze each of the three pairs of datasets with canonical correlation analysis (CCA). d, CCA finds a common mapping for two datasets. For bulk RNA-seq and single-cell RNA-seq, we first find a common set of g genes present in both datasets. Each bulk sample s i gets a coefficient a i and each cell c i gets a coefficient b i . The linear combination of all samples s 1…n arranges bulk genes along the canonical variate CV s1 and the linear combination of all cells c 1…m arranges single-cell genes along CV c1 . CCA finds the coefficients a 1…n and b 1…m that arrange the genes from the two datasets in such a way that the correlation between CV s1 and CV c1 is maximized. After CCA finds the first pair of canonical variates, the next pair is computed on the residuals, and so on.
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+ sublining fibroblasts (SC-F1) were higher in leukocyte-rich RA compared with those in OA (t test P = 2 × 10 −6 and P = 2 × 10 −3
, respectively), whereas the gene averages for CD55 + lining fibroblasts (SC-F4) were higher in OA than in leukocyte-rich RA (t test P = 5 × 10 −7 ) (Fig. 4b) . Consistent with the role of synovial fibroblasts in matrix remodeling, the sublining fibroblast subsets (SC-F1-3) expressed genes encoding extracellular matrix constituents (Fig. 4c) . HLA-DRA hi sublining fibroblasts (SC-F2) expressed genes related to MHC class II presentation and the interferon γ-mediated signaling pathway (IFI30) (Fig. 4a,c) , suggesting upregulation of MHC class II in response to interferon-γ signaling in these cells. We identified a novel sublining fibroblast subtype (SC-F3) that is characterized by high expression of DKK3, CADM1, and COL8A2 (Fig. 4a) .
To independently confirm the presence of the four fibroblast subpopulations discovered by means of scRNA-seq, we analyzed CD45 −
PDPN
+ cells in mass cytometry data and found eight putative cell clusters with differential protein levels of THY1, HLA-DR, CD34, and cadherin-11 with no obvious batch effects (Fig. 4d-g and Supplementary Fig. 3b ). CCA revealed that greater abundance of THY1 + CD34 − HLA-DR hi fibroblasts measured via mass cytometry is associated with higher expression of IL6, CXCL12, and HLA-DRA in bulk RNA-seq of the same samples, suggesting that these cells are in an active cytokine-producing state (Fig. 4h) . CCA allowed us to place mass cytometry clusters in the same space as bulk RNA-seq genes, so we could query the positions of scRNA-seq genes within this space to find the correspondence between scRNAseq clusters and mass cytometry clusters ( Fig. 4i and , t value = 8.92, df = 22.27) compared with leukocyte-poor RA and OA. Leukocyte-rich RA tissues were significantly higher infiltrated in synovial B cells (Student's one-sided t test P = 1 × 10 −3 , t value = 3.50, df = 20.56) compared with leukocyte-poor RA and OA. Center value is mean. Statistical significance levels: ****P < 1 × 10 −4 and ***P < 1 × 10
. d, Quantitative histologic inflammatory scoring of both sublining cell layer and lining layer. Leukocyte-rich RA samples (n = 19) exhibited higher (Student's one-sided t test P = 1 × 10 −3 , t value = 3.21, df = 30.66) Krenn inflammation scores than leukocyte-poor RA (n = 15) and OA tissues (n = 10) samples. Center value is mean. e,Correlation between leukocyte infiltration assessed by cytometry with histologic inflammation score (n = 44 biologically independent samples). Student's one-sided t test P = 3 × 10 −09
, t value = 7.15, df = 46.51. f, tSNE visualization of synovial cell types in OA, leukocyte-poor RA, and leukocyte-rich RA by mass cytometry density plot. ) ( Table 1 ). To validate that the protein surface markers from mass cytometry were capturing the same transcriptional populations from scRNAseq, we isolated fibroblasts from ten synovial tissue samples on the basis of surface protein levels of THY1 and HLA-DR and applied bulk RNA-seq ( Supplementary Fig. 6a ). We trained a linear discriminant analysis (LDA) classifier on fibroblast scRNA-seq data and used it to determine the most similar scRNA-seq cluster for each bulk RNAseq sample. The sorted THY1 
HLA-DR
+ fibroblasts included IL6 and CXCL12, consistent with the scRNA-seq data.
Activation states define heterogeneity among synovial monocytes. We identified four transcriptionally distinct monocyte subsets in the scRNA-seq data: IL1B + pro-inflammatory monocytes (SC-M1), NUPR1 + monocytes (SC-M2), C1QA + monocytes (SC-M3), and IFN-activated SPP1 + monocytes (SC-M4) (Fig. 5a ). In bulk RNA-seq monocyte samples from individuals with leukocyte-rich RA and OA, we found that genes associated with IL1B + monocytes (SC-M1), including NR4A2, HBEGF, PLAUR, and the IFN-activated gene IFITM3 were significantly upregulated in leukocyte-rich RA samples (t test P < 1 × 10
−4
). In contrast, marker genes associated with NUPR1 + monocytes (SC-M2) were downregulated in leukocyte-rich RA relative to OA (Fig. 5a ). Next, we took the average of the top marker genes (AUC > 0.7) for each monocyte scRNA-seq subset and tested for differential expression of these averages in the bulk RA versus OA RNA-seq data. This analysis showed that leukocyte-rich RA synovia have a greater abundance of IL1B
+ monocytes (t test P = 6 × 10
) and IFN-activated monocytes (t test P = 6 × 10 ) (Fig. 5b) . These data suggest that cytokine activation drives expansion of unique monocyte populations in active RA synovia.
Using Gene Set Enrichment Analysis (GSEA), we tested MSigDB (the Molecular Signatures Database) immunologic gene sets and found IL1B + monocytes (SC-M1) have relatively high expression levels of genes defining the lipopolysaccharide response in monocytes and macrophages (Fig. 5b) . This finding suggests that IL1B + monocytes (SC-M1) are similar to TLR-activated IL-1-producing pro-inflammatory monocytes. Among Gene Ontology gene sets, we found that SPP1
+ monocytes (SC-M4) express genes induced by type I and type II IFN ( Supplementary Fig. 8a ), including IFITM3 and IFI6 (Fig. 5a ). The transcriptional profiles of monocytes in SC-M2 and SC-M3 do not align with known activation states, possibly indicating that these clusters represent cell phenotypes tailored to the unique homeostatic needs of the synovium.
Immunofluorescence staining confirmed the presence of CD14-and IL-1β-positive cells in six tissue samples, consistent with an enrichment of the IL1B + pro-inflammatory monocyte (SC-M1) phenotype in RA synovium ( Fig. 5d and Supplementary Fig. 9a,b) .
In the mass cytometry data, we identified five CD14 + monocyte clusters (Fig. 5e-h and Supplementary Fig. 3c ). Using CCA to , t value = −5.31, df = 21.97) in OA samples. Fold changes with 95% CI. c, Pathway enrichment analysis for each cluster. Two-sided KolmogorovSmirnov test with 10 5 permutations; Benjamini-Hochberg FDR is shown. d,e, Identified subpopulations from fibroblasts (n = 25,161) and disease status from six leukocyte-rich RA samples, nine leukocyte-poor RA samples, and eight OA samples by mass cytometry on the same gating with scRNA-seq. f,g, Normalized intensity of distinct protein markers shown in tSNE visualization and averaged for each cluster heat map. h, CCA projections of mass cytometry clusters and bulk RNA-seq genes. First two canonical variates (CVs) separated genes upregulated in leukocyte-rich RA from genes upregulated in OA. HLA-DR genes are highly associated with THY1 + CD34 − HLA-DR hi by mass cytometry. i, Integration of mass cytometry clusters with scRNA-seq clusters based on the top markers (AUC > 0.7) for each scRNA-seq cluster using top ten canonical variates in the low-dimensional CCA space. We computed the spearman correlation between each pair of scRNA-seq cluster and mass cytometry cluster in the CCA space and performed permutation test 10 4 times. Z score is calculated on the basis of permutation P value. We observed HLA-DRA hi sublining fibroblasts by scRNA-seq are strongly correlated with THY1 − mono cytes in mass cytometry and were inversely correlated with inflam matory monocyte populations (z score = 2.7) (Fig. 5j and Table 1 ).
To confirm that putative populations from mass cytometry correspond to those identified by scRNA-seq clusters, we sorted CD14 + monocytes from four synovial tissue samples using CD11c and CD38 protein markers and assayed the cells via RNA-seq ( Supplementary Fig. 6c ). Importantly, we found that CD14 25.5 (7.5-101.8) ResouRce Nature ImmuNology
Heterogeneity in synovial CD4 and CD8 T cells defined by effector functions. We found three CD4 + and three CD8 + T cell subsets in the scRNA-seq data (Fig. 6a) . CCR7 + T cells (SC-T1) expressed genes in the MSigDB immunologic gene set for central memory T cells (Fig. 6a,c) . The two other CD4
+ populations, FOXP3 + T reg cells and PDCD1 + T PH and T FH cells, were marked by high expression of FOXP3 (SC-T2) and CXCL13 (SC-T3) in examination of differentially expressed genes between these two clusters 18 (Supplementary Fig. 8c ). CXCL13, a chemokine expressed by T PH cells, was upregulated in bulk-sorted T cells (
leukocyte-rich RA compared samples with OA (t test P = 1.2 × 10 −4 ) (Fig. 6a) . We found that the average of marker genes for T PH and T FH cells (SC-T3) (AUC > 0.7) was higher in leukocyte-rich RA than that in OA samples (t test P = 0.01) (Fig. 6b) , thus suggesting greater abundance of T PH and activated T cells in RA than in OA. We identified three CD8 + T cell subsets characterized by distinct expression patterns of effector molecule genes GZMK, GZMB, GZMA, and GNLY (Fig. 6a) . We defined these populations as GZMK + (SC-T4), GNLY + GZMB + cytotoxic T lymphocytes (CTLs) (SC-T5), and GZMK + monocytes (SC-M2) with a mixture of leukocyte-poor RA and OA cells, C1QA + (SC-M3), and IFN-activated monocytes (SC-M4). Differential analysis by bulk RNA-seq on leukocyte-rich RA samples (n = 17) and OA samples (n = 13) revealed upregulation and downregulation of cluster marker genes. Effect sizes with 95% CI are given. b, By querying the bulk RNA-seq, we found scRNA-seq cluster IL1B + pro-inflammatory monocytes (two-sided Student's t test P = 6 × 10 , t value = −5.62, df = 26.81) in leukocyte-rich RA. Error bars indicate mean and 95% CI. c, Pathway enrichment analysis indicates the potential pathways for each subset. Two-sided Kolmogorov-Smirnov test with 10 5 times permutation was performed; Benjamini-Hochberg was used to control the FDR of multiple tests. The standard names for the immunological gene sets from top to bottom are as follows: genes downregulated in neutrophils versus monocytes (GSE22886); genes downregulated in healthy myeloid cells versus SLE myeloid cells (GSE10325); genes downregulated in control microglia cells versus those 24 h after stimulation with IFNG (GSE1432); genes downregulated in unstimulated macrophage cells versus macrophage cells stimulated with lipopolysaccharide (GSE14769); genes upregulated in monocytes treated with lipopolysaccharide versus monocytes treated with control IgG (GSE9988); genes upregulated in monocytes versus myeloid dendritic cells (mDC) (GSE29618); genes upregulated in monocytes versus plasmacytoid dendritic cells (pDC) (GSE29618). d, Detection of pro-inflammatory IL-1β in inflamed synovium by multicolor immunofluorescent staining with antibodies to CD14 (red), IL-1β (green), and counterstained with DAPI (blue) identified CD14 + IL-1β + cells (white arrow). The experiment was repeated >5 times with staining of six independent leukocyte-rich RA samples with similar results. Image was acquired at ×200 magnification. Scale bar, 50 μm. e,f, Identified subpopulations from monocytes (n = 15,298) and disease status from six leukocyte-rich RA sample, nine leukocyte-poor RA samples, and 11 OA samples by mass cytometry on the same gating with scRNA-seq. g,h, Normalized intensity of distinct protein markers by tSNE visualization, averaged for each cluster in the heatmap. i, Integration of identified mass cytometry clusters with bulk RNA-seq reveals genes that are associated with CD11c ResouRce Nature ImmuNology
(SC-T6) also expressed HLA-DPA1 and HLA-DRB1 and other genes suggestive of an effector phenotype (Fig. 6a,c) .
To confirm these findings, we applied intracellular staining to tissues from RA samples and RNA-seq to sorted CD8 + T cells.
Intracellular staining of GZMK and GZMB proteins in disaggregated tissue samples from patients with RA revealed that most CD8 + T cells in synovial tissue express GZMK ( Supplementary  Fig. 10a ). Furthermore, we found that most HLA-DR + CD8 + T cells 
Treg cells Effector CD8 T cells Central memory CD4 T cells Effector memory CD4 T cells T follicular helper
IFNγ
+ (white arrow) in inflamed RA synovium via multicolor immunofluorescent staining with antibodies to CD3 (green), CD8 (red), IFNγ (white), and counterstained with DAPI (blue). The experiment was repeated >5 times with staining of six independent leukocyte-rich RA samples with similar results. Image was acquired at ×200 magnification. Scale bar, 50 μm. e,f, Identified subpopulations from T cells (n = 19,985) and disease status from six leukocyte-rich RA samples, nine leukocyte-poor RA samples, and 11 OA samples with mass cytometry. g,h, Distinct patterns of protein markers with tSNE and heat map that define these clusters. i, Integration of identified mass cytometry clusters with bulk RNA-seq using CCA reveals bulk genes that are associated with CD4 ResouRce Nature ImmuNology express both GZMB and GZMK by intracellular protein staining ( Supplementary Fig. 10b ). In a comparison of seven synovial tissue samples, CD8 + T cells had a higher proportion of IFN + cells than CD4 + T cells from the same sample ( Supplementary  Fig. 10c,d) . We also applied immunofluorescence to six synovial tissue samples and found that IFN + CD3 + CD8 + T cells were higher in frequency in RA than OA (Fig. 6d and Supplementary Fig. 9c,d) . Overall, these results closely mirror the findings from the scRNAseq clusters.
Using mass cytometry, we identified nine putative T cell clusters among the synovial T cells ( (Fig. 6e-h and Supplementary Fig. 3d ). By integrating bulk RNA-seq with mass cytometry cluster abundances, we found that higher gene expression of CXCL13 and inhibitory receptors TIGIT and CTLA4 was associated with a greater abundance of the CD4 (Fig. 7a) . Findings from GSEA with Gene Ontology pathways suggested that SC-B1, SC-B2, and SC-B3 clusters represent activated B cells (Supplementary Fig. 8b ). GSEA with MSigDB immunological gene sets revealed that SC-B1 cells expressed naïve B cell genes, whereas SC-B2 and SC-B3 cells expressed IgM and IgG memory B cell genes (Fig. 7b) . SC-B3 cells expressed high levels of ITGAX and TBX21 (T-bet), which are markers of autoimmunity-associated B cells 28, 29 ( Figs. 3f and 7a Interferon-stimulated genes (GBP1 and ISG15) were also expressed in ABCs (SC-B3) and upregulated in leukocyte-rich RA (Fig. 7a) . Although ABCs (SC-B3) constitute a relatively small proportion of all B cells, they were almost exclusively derived from two patients with leukocyte-rich RA (Fig. 3b) . To confirm the presence of ABCs in human tissues, we applied immunofluorescence staining to six synovial tissue samples. RA synovium had increased numbers of CD20
+ B cells compared with OA synovium. Specifically, we observed ABC cells in tissue sections from the same inflamed tissue samples that had a high proportion of ABCs by scRNA-seq analysis ( Fig. 7c and Supplementary Fig. 9e,f) .
We identified ten putative B cell clusters in the mass cytometry data (CD45 + CD3 − CD14 − CD19 + ) (Fig. 7d-g and Supplementary  Fig. 3e ). CCA analysis showed that samples with higher gene expression of CD38, MZB1, and plasma cell differentiation factor XBP1 had greater abundance of CD38 ++ CD20 − IgM − IgD − plasmablasts (Fig. 7h) 
CD11c
+ cells by surface protein markers correspond to SC-B3 (ABCs), we flow sorted CD19
+
CD11c
+ cells from an independent cohort of six RA synovial samples and applied RNA-seq ( Supplementary Fig. 6b ). We show that these RNA-seq profiles are most consistent with that of ABC cells ( Supplementary Fig. 7i−k) . In these sorted samples, we found more putative marker genes (for example, ZEB2 and CIITA) and interferon-induced genes (IFITM3 and IFI27) for the ABC population ( Supplementary Fig. 7l ).
Inflammatory pathways and effector modules revealed by global single-cell profiling. We used bulk and single-cell transcriptomics of sorted synovial cells to examine pathologic molecular signaling pathways. First, PCA on post-quality control OA and RA bulk RNA-seq samples ( Supplementary Fig. 11a,b) showed that cell type accounted for most of the data variance. Each cell type expressed specific marker genes: PDGFRA for fibroblasts, C1QA for monocytes, CD3D for T cells, and CD19 for B cells (Supplementary Fig. 11c ). Within each cell type, PCA showed that leukocyte-rich RA samples separated from OA and leukocyte-poor RA samples ( Supplementary Fig. 11d-g ). Differential gene expression analysis between leukocyte-rich RA and OA (FC > 2 and FDR < 0.01) revealed genes upregulated in leukocyte-rich RA tissues: 173 in fibroblasts, 159 in monocytes, ten in T cells, and five in B cells. To define the pathways relevant to leukocyte-rich RA, we used GSEA weighted by gene effect sizes on Gene Ontology pathways and identified type I interferon response and inflammatory response (monocytes and fibroblasts) (Supplementary Fig. 11h,i) , Fc receptor signaling (monocytes), NF-kappa B signaling (fibroblasts), and interferon gamma (T cells) (Fig. 8a) . Leukocyte-rich RA samples had significantly higher expression of genes in fibroblasts and monocytes: inflammatory response genes (PTGS2, PTGER3, and ICAM1), interferon response genes (IFIT2, RSAD2, STAT1, and XAF1), and chemokine or cytokine genes (CCL2 and CXCL9) (Fig. 8b) , consistent with a coordinated chemotactic response to interferon activation. T cells had upregulation of interferon regulatory factors (IRFs), including IRF7 and IRF9, and monocytes had upregulation of IRF7, IRF8 and IRF9. Taken together, results from the pathway analysis suggests crosstalk between immune and stromal cells in leukocyte-rich RA synovia. Inflammatory response genes upregulated in leukocyte-rich RA had comparable expression levels between leukocyte-poor RA and OA synovial cells (Fig. 8b) Next, we asked whether inflammatory cytokines upregulated in leukocyte-rich RA are driven by global upregulation within a single synovial cell type or specific upregulation within a discrete cell subset defined by scRNA-seq. Whereas TNF was produced at a high level by multiple monocyte, B cell and T cell populations; IL6 expression was restricted to HLA-DRA hi sublining fibroblasts (SC-F2) and a subset of B cells (SC-B1) (Fig. 8c) ; CD8 + T cells, rather than CD4 + T cells, were the dominant source of IFNG transcription in leukocyte-rich synovia.
We also observed cell subset-specific responses to inflammatory pathways. Toll-like receptor signaling pathway was enriched in B cells and monocytes in leukocyte-rich RA tissues (Fig. 8a) . At the single-cell level, TLR10 was only expressed by activated B cells (Fig. 8c) , indicating that TLR10 has a functional role within the B cell lineage. In contrast, TLR8 was elevated in all RA monocyte subsets. The hematopoietic cell-specific transcription factor IRF8 was expressed in a significant fraction of monocytes and B cells that cooperatively regulate differentiation of monocytes and activated B cells in RA synovium. SLAMF7 is highly expressed by pro-inflammatory monocytes (SC-M1), IFN-activated monocytes (SC-M4), CD8 + T cells, and plasmablasts (SC-B4 Supplementary Fig. 3f ).
Discussion
Using multi-model, high-dimensional synovial tissue data, we defined stromal and immune cell populations overabundant in RA and described their transcriptional contributions to essential inflammatory pathways. Recognizing the considerable variation in disease duration and activity, treatment types, and joint histology scores 32 , we elected to use a molecular parameter, based on percent leukocytes of the total cellularity, to classify our samples at the local tissue level. We note that differences in leukocyte enrichment of joint replacement samples and biopsy samples were best explained by leukocyte infiltration and not by the histological scores ( Supplementary Figs. 1 and 11d-g ). T-bet CD11c 
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This study and a previous study 33 have highlighted sublining fibroblasts as a potential therapeutic target in RA. Sublining fibroblasts are a major source of pro-inflammatory cytokines such as IL6 (Fig. 4) , and a specific subset of sublining fibroblasts expressing MHC II (SC-F2, THY1
+ CD34 -HLA-DR hi ) was >15-fold expanded in RA tissues. Further studies are needed to define molecular mechanisms that regulate sublining fibroblast expansion in RA. T cells, B cells, and monocyte proportions track with expression of individual fibroblast genes (Supplementary Fig. 11j ). We found DNASE1L3, a gene whose loss of function is associated with RA 34 and systemic lupus erythematosus 35 to be highly expressed in CD55 + lining fibroblasts (SC-F4) (Fig. 4a) . We identified a novel fibroblast subset (SC-F3) with high expression of DKK3 (Fig. 4) , encoding Dickkopf3, a protein upregulated in OA that prevents cartilage degradation in vitro 36 . Transcriptional heterogeneity in the synovial monocytes indicated that distinct RA-enriched subsets are driven by inflammatory cytokines and interferons (Fig. 5) . This suggests monocytes may be   IL1B  IL1RN  IL15  CCL3  CXCL8  CXCL11  TLR8  MYD88  NFKB1  PTPN2  PTGS2  PTGER3  ICAM1  OAS1  BST2  IFIT2  IFI27  RSAD2  STAT1  XAF1  CCL2  CX3CL1  CXCL9  CXCL12  IL6  C3  CDH11  PDGFRB  MMP1  ACTA2  TRAF3  SLAMF7  NFKB2  IRF8  IRF7  IRF1  IRF9  GBP5  IRF3  HSPD1  CXCL13 5 permutations was performed on 18 leukocyte-rich RA samples, 17 leukocyte-poor RA samples, and 14 OA samples. b, Bulk RNA-seq profiling of genes obtained from the significantly enriched pathways from a shows the averaged gene expression from each group (18 leukocyte-rich RA, 17 leukocyte-poor RA, and 14 OA) normalized across all cell type samples. c, scRNA-seq profiling resolved that inflammatory cytokines/chemokines, interferon responsive, and inflammatory responsive genes were driven by a global upregulation within a synovial cell type or discrete cell states.
ResouRce Nature ImmuNology differentially polarized by unique cytokine combinations in local microenvironments. These newly identified inflammatory phenotypes align with RA therapeutic targets, including anti-TNF therapies and interferon pathway JAK kinase inhibitors 37 . The NUPR1 + (SC-M2) monocytes were inversely correlated with tissue inflammation, and expressed high levels of monocyte tissue remodeling factors such as MERTK 38 (Fig. 5) . Alternatively, NUPR1 + markers such as osteoactivin (GPNMB) and cathepsin K (CTSK) may indicate a subset of osteoclast progenitors that control bone remodeling 37, 39 (Fig. 5) . Furthermore, spatial studies-particularly focused on lining versus sublining, perivascular and lymphocyte aggregateassociated monocytes-will help understand the functional roles of these subsets.
Single-cell classification of T cell subsets in RA synovium demonstrated CD4
+ T cell heterogeneity that is consistent with distinction between the homing capacity and effector functions of these subsets. Consistent with previous studies, we observed expansion of PDCD1 +
CD4
+ T PH cells (SC-T3) within leukocyte-rich RA. We also found CD8 + T cell subsets (SC-T4-6) characterized by a distinct granzyme expression pattern (Fig. 6a) . A larger study may be better powered to differentiate the relative expansion of individual subpopulations.
This study is the first to report the presence of autoimmuneassociated B cells (SC-B3) by transcriptomic sequencing in human leukocyte-rich synovial RA and, in fact, in any human autoimmune target tissue. This B cell population was first reported in aging mice and subsequently seen in autoimmune mice and peripheral blood of patients with SLE 31, 40 . We observed a heterogeneity of CD11c +
B cells detectable in both IgD
+ and switched B cell populations by mass cytometry. The gene expression of other ABCs markers suggests a balance between germinal center (IRF8 and AID) and plasma cell (SLAMF7) differentiation within the RA synovium. We have few B cells from OA synovia (Fig. 2b) , which limited our ability to identify RA-associated B cell subsets through case-control comparisons (Fig. 7g) .
A critical unmet need in RA is identifying therapeutic targets for patients failing to respond to disease-modifying antirheumatic drugs 41 . We observed upregulation of chemokines (CXCL8, CXCL9, and CXCL13), cytokines (IFNG and IL15, refs. 42, 43 ), and surface receptors (PDGFRB and SLAMF7) in distinct immune and stromal cell populations, suggesting potential novel targets. This study was enabled by advances in the statistical integration of single-cell data and our recent work optimizing robust methodologies for disaggregation of synovial tissue 22 . We developed advanced strategies to integrate multiple molecular datasets by modulating technical artifact from single-cell technologies 44 while emphasizing biological signals. CCA has been successfully employed in other contexts to integrate highdimensional biological data 45, 46 . Our CCA-based strategy analyzed scRNA-seq data using canonical variates that capture variance that are present in both single-cell and bulk RNA-seq data. The shared variances likely represent biological trends and not technical factors that would probably be uncorrelated in these two independent datasets. We further confirmed that the identified scRNA-seq clusters are well correlated with the bulk RNA-seq data and also the mass cytometry data ( Supplementary Figs. 12 and 13) .
The two single-cell modalities used in this study, mass cytometry and scRNA-seq, complement each other. Single-cell RNA-seq captures expression of thousands of genes, but at the cost of sparse data 47 . Mass cytometry captures hundreds of thousands of individual cells, but measures a limited number (~40) 48 of preselected markers. However, each of these markers is supported by decades of experimental evidence that they are useful for defining cellular heterogeneity 49 . To make the analysis consistent, we gated mass cytometry cells on the same markers upon which the scRNAseq was gated. Combining mass cytometry with the extended dimensionality of scRNA-seq enables quantification of well-established cell populations and discovery of novel cell states, such as the CD8 + T cell states noted here. As an ongoing AMP phase 2 study, we are examining larger numbers of ungated cell populations from ~100 synovial tissue patients with RA by capturing mRNA and protein expression simultaneously 50 with detailed clinical data and ultrasound score evaluation of synovitis. We anticipate that this larger study will enable us to not only discover additional subpopulations, but to better define their link to clinical subphenotypes.
It is essential to interrogate the tissue infiltration of diseases other than RA, including SLE, type I diabetes, psoriasis, multiple sclerosis, and other organ-targeting conditions. Application of multiple single-cell technologies together can help define key novel populations, thereby providing new insights about etiology and potential therapies.
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Methods Study design and patient recruitment. The study was performed in accordance with protocols approved by the institutional review board: a multicenter, crosssectional study of individuals undergoing elective surgical procedures and a prospective observational study of synovial biopsy specimens from patients with RA aged ≥18 years, with at least one inflamed joint, recruited from ten contributing sites in the network. Synovial tissues were obtained from joint replacement procedures or ultrasound-guided biopsies; samples were then cryopreserved in cryopreservation media Cryostor CS10 (Sigma-Aldrich) and transited to a central technology site.
Histological assessment of synovial tissue and quality control. Synovial tissue quality and grading of synovitis were evaluated in formalin-fixed, paraffinembedded sections by histologic analysis (H&E staining). Specimens were identified as synovium via the presence of a lining layer or by characteristic histologic features of synovium, including the presence of loose fibrovascular or fatty tissue lacking a lining layer. Samples consisting of dense fibrous tissue, joint capsule or other tissues were determined to not be synovium. For each histological and molecular analysis, we generated pooled data from six to eight separate fragments from different sites in the same joint. Thus, these data should be representative of the whole tissue and mitigate much of the biopsy site-to-site variability. Krenn lining scores (0-3) and inflammation scores (0-3) for each tissue sample were determined independently by three pathologists 25 .
Tissue disaggregation for mass cytometry and RNA-sequencing. For pipeline analysis, synovial tissue samples stored in cryovials were disaggregated into singlecell suspension as described. Briefly, synovial tissue fragments were separated mechanically and enzymatically in digestion buffer (Liberase TL (Sigma-Aldrich) 100 μg/ml and DNase I (New England Biolabs) 100 μg/ml in RPMI) in a 37 o C water bath for 30 min. Single-cell suspensions from disaggregated synovial tissues were assessed for cell quantity and cell viability using Trypan Blue. For samples with more than 200,000 viable synovial cells, 50% of all synovial cells were allocated for analysis by mass cytometry, and the remaining cells were allocated for RNA-seq. For samples with fewer than 200,000 viable synovial cells, all synovial cells were utilized for RNA-seq analysis.
Synovial cell sorting strategy for RNA sequencing. Synovial T cells, B cells, monocytes, and fibroblasts were isolated from disaggregated synovial tissue, as described previously 22 . Briefly, disaggregated synovial cells were stained with antibodies to CD45 (HI30), CD90 (5E10), podoplanin (NZ1. Flow sorting strategy for bulk RNA-seq experimental validation. For bulk RNA-seq validation experiments, RA and OA synovial tissue were disaggregated, and synovial cells were stained with cell-type-specific antibody panels. For each cell subset, up to 1,000 cells were collected directly into buffer TCL (Qiagen). Antibody panels used to define cell subsets are: fibroblasts: CD90 (5E10), podoplanin (NZ1.3), HLA-DR (G46-6); B cell subsets: HLA-DR (G46-6), CD11c (3.9), CD19 (SJ25C1), CD27 (M-T271), IgD (IA6-2), CD3 (UCHT1), CD14 (M5E2), CD38 (HIT2);monocyte subsets: CD14-BV421 (M5E2), CD38-APC (HB-7), and CD11c-PECy7 (B-ly6). Immediately prior to sorting, DAPI or LIVE/ DEAD viability dye was added to cell suspensions, and cells were passed through a 100 μm filter. Synovial cell subsets were sorted by flow cytometry gating schema shown in Supplementary Fig. 6 . In all, we sorted THY1 -DR -populations from four OA samples, THY1 
CD11c
+ population from three RA samples, and plasma cells from three RA samples.
To validate the identified single-cell populations using bulk RNA-seq, we fit an LDA (linear discriminant analysis) classifier on the scRNA-seq cell clusters and then classified each flow-sorted bulk RNA-seq sample. For each cell type, (1) we trained an LDA model on the scRNA-seq clusters with the top 500 marker genes for each cluster; (2) we applied this LDA model to classify each sample of bulk sorted cells and estimated the maximum posterior probability for each sample. In summary, we tested whether we could sort new cells from new, independent samples and see the same gene expression profiles in the new bulk samples as the original scRNA-seq samples.
Multicolor immunofluorescent staining of paraffin synovial tissue. Briefly, 5mm-thick formalin-fixed paraffin sections were incubated in a 60 o C oven to melt then paraffin. Slides were quickly transferred to xylenes to completely dissolve the paraffin, and after 5 min, were transferred to absolute ethanol. Slides were left in absolute ethanol for 5 min and then transferred to 95% ethanol. At the end of the 5min immersion in 95% ethanol, slides were rinsed several times with distilled water and transfer to a plastic coplin jar filled with 1× DAKO retrieval solution (S1699, Dakocytomation). Antigens were unmasked by immersing a plastic coplin jar in boiling water for 30 min. Slides cooled for 10 min at room temperature and washed several times with distilled water. Nonspecific binding was blocked with 5% normal donkey serum (017-000-121, Jackson ImmunoResearch Laboratories) dissolved in PBS containing 0.1% Tween 20 and 0.1% Triton X-100. Without washing, blocking solution was removed from slides, and combinations of primary antibodies were added to PBS containing 0.1% Tween 20 and 0.1% Triton X-100. Primary antibodies to detect IFNγ 
Estimation of number of cells by counting nuclei.
To estimate number of cells, we counted the number of nuclei in five random ×200 magnification fields that showed synovial lining with Image J NIH software. Briefly, original color TIFF files were first transformed into 8-bit grayscale images. We used similar settings to adjust threshold in 8-bit images (lower threshold level: 0, upper threshold level: 60). Next, we used process:binary:watershed to separate nuclei. In the analyze icon, we selected 'analyze particles' , and we used equal settings to count particles in our images (size (pixel 2 ): 50-infinity, circularity 0.00-1.00, show: outlines), and we selected to display results. We visually confirmed that individual nuclei were outlined in the final image, and calculate the average number of cells/×200 field in individual samples.
Tissue sample classification by leukocyte infiltration. We classified RA tissue samples into leukocyte-poor RA and leukocyte-rich RA on the basis of the Mahalanobis distance from OA samples computed on leukocyte abundance measured via flow cytometry. We first took OA samples as a reference and calculated a multivariate normal distribution of the percentages of live T cells, B cells, and monocytes. Here, we used the Mahalanobis function in R: data x = a matrix of all 51 samples by flow gates of T cells, B cells, and monocytes; center = mean of T cells, B cells, and monocytes for all OA samples; covariance = covariance of T cells, B cells, and monocytes for all OA samples. We calculated the square root to get the Mahalanobis distance for each sample:
We then defined the maximum value of all OA samples (4.5) as a threshold to define 19 leukocyte-rich RA (>4.5) and 17 leukocyte-poor RA (<4.5) samples in our cohort (Supplementary Fig. 1d ).
Bulk RNA-seq gene expression quantification. We sorted cells into the major immune and stromal cell populations: T cells, B cells, monocytes, and synovial fibroblasts. We then performed RNA sequencing. Full-length cDNA and sequencing libraries were performed using Illumina Smart-eq2 protocol 51 .
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Libraries were sequenced on MiSeq from Illumina to generate 35 base paired-end reads. Reads were mapped to Ensembl version 83 transcripts using kallisto 0.42.4 and summed expression of all transcripts for each gene to get transcripts per million (TPM) for each gene.
Bulk RNA-seq quality control. For quality control of bulk RNA-seq data, we began by defining common genes as the set of genes detected with at least one mapped fragment in 95% of the samples. Then, for each sample, we computed the percent of common genes detected in that sample. Low-quality samples are those that have less than 99% of common genes detected, and these were discarded. We found that the low-quality samples also had low cell counts ( Supplementary  Fig. 11a ). After discarding 25 low-quality samples, we used 167 good-quality samples, including 45 fibroblast samples, 46 monocyte samples, 47 T cell samples, and 29 B cell samples in all bulk RNA-seq analyses. Cell lineage markers, PDGFRA, C1QA, CD3D, and CD19 are expressed selectively by fibroblasts, monocytes, T cells, and B cells, respectively (Supplementary Fig. 11c ).
Single-cell RNA-seq gene expression quantification. Single-cell RNA-seq was performed using the CEL-Seq2 method 47 with the following modifications. Single cells were sorted into 384-well plates containing 0.6 µl 1% NP-40 buffer in each well. Then, 0.6 µl dNTPs (10 mM each; NEB) and 5 nl of barcoded reverse transcription primer (1 µg/µl) were added to each well along with 20 nl of ERCC spike-in (diluted 1:800,000). Reactions were incubated at 65 °C for 5 min, and then moved immediately to ice. Reverse transcription reactions were carried out, as previously described (Hashimshony et al., 2016) , and cDNA was purified using 0.8X volumes of Agencourt RNAClean XP beads (Beckman Coulter). In vitro transcription reactions (IVT) were performed, as described followed by EXO-SAP treatment. Amplified RNA (aRNA) was fragmented at 80 °C for 3 min and purified using Agencourt RNAClean XP beads (Beckman Coulter). The purified aRNA was converted to cDNA using an anchored random primer and Illumina adaptor sequences were added by PCR. The final cDNA library was purified using Agencourt RNAClean XP beads (Beckman Coulter). Paired-end sequencing was performed on the HiSeq 2500 in High Output Run Mode with a 5% PhiX spike-in using 15 bases for Read 1, 6 bases for the Illumina barcode and 36 bases for Read 2. We mapped Read2 to human reference genome hg19 using STAR 2.5.2b, and removed samples with outlier performance using Picard. We quantified gene levels by counting UMIs (Unique Molecular Identifiers) and transforming the counts to log 2 (CPM + 1) (Counts Per Million).
Single-cell RNA-seq quality control. For quality control of single-cell RNA-seq data, we filtered out molecules that are likely to be contamination between cells, and we used several metrics to exclude poor quality cells. We identified molecules that are likely to represent cell-to-cell cross-contamination as follows. Many singlecell RNA-seq library preparation protocols include pooling and amplification of cDNA molecules from a large number of cells. This can introduce cell-to-cell contamination. We found that molecules represented by a small number of reads are more likely to be contaminant molecules derived from other cells. We developed a simple algorithm to set a threshold for the minimum number of reads per molecule, and we ran it separately for each quadrant of 96 wells in each 384-well plate. We used 2 marker genes expected to be exclusively expressed in each of the four cell types: PDGFRA and ISLR for fibroblasts, CD2 and CD3D for T cells, CD79A and RALGPS2 for B cells, and CD14 and C1QA for monocytes. We counted nonzero expression of these genes in the correct cell type as a true positive and nonzero expression in the incorrect cell type as a false positive. Then we tried each threshold for reads per molecule from 1-20 and chose the threshold that maximizes the ratio of true positive to false positive ( Supplementary Fig. 14) . This left us with 7,127 cells and 32,391 genes. Next, we discarded cells with fewer than 1,000 genes detected with at least one fragment. We also discarded cells that had more than 25% of molecules coming from mitochondrial genes. This left us with 5,265 cells. We discarded genes that had nonzero expression in fewer than 10 cells. We show all post-QC single cells based on the number of genes detected and percent of molecules from mitochondrial genes for each identified cluster ( Supplementary Fig. 15 ).
Mass cytometry sample processing and quality control. We collected 6 leukocyte-rich, 9 leukocyte-poor RA, and 11 OA samples for mass cytometry analysis, and processed the samples, as described previously 22 . Briefly, we analyzed samples on a Helios instrument (Fluidigm) after antibody staining and fixation (Supplementary Table 2 ). Mass cytometry data were normalized using EQ Four Element Calibration Beads (Fluidigm), as previously described Integrative computational pipeline for scRNA-seq clustering. We developed a graph-based unbiased clustering pipeline based on canonical correlation analysis to take advantage of the shared variation between single-cell RNA-seq and bulk RNA-seq. We used this computational pipeline to analyze single cells from each cell type. The overall flowchart is shown in Supplementary Fig. 2a . Details of each step are as follows: that arrange the genes from the two datasets in such a way that the correlation between CV s1 and CV c1 is maximized. After CCA finds the first pair of canonical variates, the next pair is computed on the residuals, and so on. 3. We calculated the cell-to-cell similarity matrix using the Euclidean distance on the top ten CCA canonical variates. 4. We built up a k-nearest neighbors (KNN) graph based on the cell-to-cell similarity matrix (Euclidean distance) based on local ordinal embedding (LOE), a graph embedding method. We then converted the KNN neighbor relation matrix into an adjacency matrix using the graph.adjacency function from the igraph R package. 5. We clustered the cells using the Infomap algorithm for community detection by applying a cluster_infomap function from the igraph R package to decompose the cell-to-cell adjacency matrix into major modules by minimizing a description of the information flow. 6. We then constructed a low dimensional embedding using tSNE based on the cell-to-cell distance matrix using the following parameters: perplexity = 50 and theta = 0.5. 7. We identified and prioritized significantly differentially expressed genes for each distinct cluster on the basis of percent of non-zero-expressing cells, AUC score 54 , and fold change. 8. For pathway analysis, we downloaded gene sets from Gene Ontology (GO) terms in April 2017 (refs. 55, 56 ). These gene sets included 9,797 GO terms and 15,693 genes. We also used the immunological signatures from 4,872 hallmark gene sets from MSigDB 57 to test enrichment of all the tested genes sorted by decreased AUC scores for each cluster by 10 5 permutation tests 55 . We used the liger R package (https://github.com/JEFworks/liger) to conduct GSEA.
To identify the most reasonable and stable clusters, we ran this pipeline repeatedly while tuning the number of top canonical variates (4, 8, 12, 16, and 20) that were incorporated for the cell-to-cell similarity matrix and the number of k (50, 100, 150, 200, 250, and 300) to build up the k-nearest neighbor graph. We chose the clusters that yielded the greatest number of differentially expressed genes. We used Silhouette analysis 58, 59 on the cell-to-cell Euclidean distance matrix to evaluate our clustering results (Supplementary Fig. 2b ). For each cell, the silhouette width s(i) is defined as follows:
where a(i) is the average dissimilarity between a cell and all the other cells in the same cluster and b(i) is the average distance between a cell and all cells in the nearest cluster to which the cell does not belong. The measure range is [−1, 1], where a value near 1 indicates a cell is far from neighboring clusters, a value near 0 indicates a cell is near a decision boundary, and a value near −1 indicates the cell is closer to a neighboring cluster than its own cluster. Thus, for each pair of single-cell RNA-seq and bulk RNA-seq, we ran our pipeline on the shared samples that have both datasets for each cell type (Fig. 1b) . For integrating fibroblast data, we used 45 bulk RNA-seq samples, 1,844 single cells and 7,016 shared highly variable genes; for integrating monocyte data, we used 47 bulk RNA-seq samples, 750 single cells and 7,016 shared highly variable genes; for integrating T cell data, we used 47 bulk RNA-seq samples, 1,716 single cells and 7,003 shared highly variable genes; for integrating B cell data, we used 29 bulk RNA-seq samples, 1,142 single cells and 7,023 shared highly variable genes.
Mass cytometry clustering.
We created mass cytometry datasets for analysis by concatenating cells from all individuals for each cell type. For donors with more than 1,000 cells, we randomly selected 1,000 cells to ensure that samples were equally represented. In this way, we created downsampled datasets of 25,161 fibroblasts from 23 patients, 15,298 monocytes from 26 patients, 19,985 T cells from 26 patients, and 8,179 B cells from 23 patients for analysis. We then applied the tSNE algorithm (Barnes-Hut implementation) to each dataset using the Integration of bulk RNA-seq with mass cytometry. We used CCA to associate the abundances of mass cytometry clusters with gene expression in bulk RNA-seq. We started by selecting the samples that had both data types. The mass cytometry data matrix has samples and clusters, where the values represent proportions of cells from each sample in each cluster. The bulk RNA-seq data matrix has samples and genes, where the values represent proportions of gene abundance from each sample in each gene. CCA identifies canonical variates (a linear combination of bulk RNAseq genes and a linear combination of mass cytometry cluster proportions) that maximize correlation of samples along each canonical variate. In other words, it tries to arrange samples from each dataset in a similar order along each canonical variate. We ran CCA separately for fibroblasts, monocytes, T cells, and B cells. For fibroblasts, we associated 2,299 genes with 8 mass cytometry clusters on 22 samples. For monocytes, we associated 2,161 genes with 5 mass cytometry clusters on 25 samples. For T cells, we associated 2,255 genes with 9 mass cytometry clusters on 26 samples. For B cells, we associated 22,95 genes with 10 mass cytometry clusters on 17 samples.
Finding correspondence between scRNA-seq clusters and mass cytometry clusters.
1. For each cell type, we ran CCA with mass cytometry clusters with bulk RNAseq. Each gene is correlated with each canonical variate (CV). Also, each mass cytometry cluster is correlated with each CV. By visualizing these correlations, we can see the positions of bulk RNA-seq genes and mass cytometry clusters in the same space (Fig. 4h) . 2. We then associated single-cell RNA-seq clusters with mass cytometry clusters by projecting cluster markers (AUC > 0.7) for each single-cell RNA-seq cluster in the CCA space acquired from step 1). 3. We took the average across the cluster marker genes for each single-cell RNAseq cluster for each CV and obtained an "average CV" matrix. 4. Based on the "average CV" matrix, we computed Spearman correlation between the scRNA-seq average CV and the CV for mass cytometry clusters. 5. Next, we generated a null distribution for the Spearman correlations by shuffling the scRNA-seq gene names and then repeating steps 2-4 10,000 times. 6. For the 10,000 replicates of CCA matrix, we repeated step 2 to step 5. Then, we counted how many times the correlation of each pair was greater than the observed value from step 4). Differential expression analysis with bulk RNA-seq. We classified all the samples into OA, leukocyte-poor RA, and leukocyte-rich RA synovial tissues on the basis of the quantitative analysis of T cells, B cells, and monocytes by flow cytometry. PCA on bulk RNA-seq samples showed separation of leukocyterich and leukocyte-poor RA on the first or second principal components. For differential analysis, we used the limma R package to identify significantly differentially expressed genes. We used the Benjamini-Hochberg method to estimate false discovery rate (FDR).
Identification of markers for distinct scRNA-seq clusters. On the basis of singlecell RNA-seq clusters, we identified cluster marker genes by comparing the cells in one cluster with all other clusters from the same cell type, based on log 2 (CPM + 1). We prioritized cluster marker genes using three criteria: (1) percent of non-zero expressing cells >60%; (2) are under the receiver-operator curve (AUC) 54 >0.7; and (3) fold change (FC) >2.
Intracellular flow cytometry of synovial tissue T cell stimulation. Disaggregated synovial tissue cells were incubated with Fixable Viability Dye (eBioscience) and Fc-blocking antibodies (eBioscience), then stained for surface markers in Brilliant Stain Buffer (BD Bioscience). Cells were then fixed and permeabilized using an intracellular staining kit (eBioscience), then subjected to intracellular staining for granzymes or cytokines. Antibodies used in this study include anti-CD45 (clone HI30) from BD Biosciences; anti-CD3 (clone UCHT1), anti-CD8 (clone SK1), anti-CD14 (clone M5E2), anti-CD4 (clone RPA-T4), anti-HLA-DR (clone L243), antigranzyme B (clone GB11), and anti-granzyme K (clone GM26E7) from Biolegend; and anti-IFNG (clone 4 S.B3) and anti-TNF (clone MAb11) from eBioscience. Data were collected on a BD Fortessa flow cytometer and analyzed using FlowJo 10.5 software. Disaggregated synovial tissue cells were incubated with a cell stimulation cocktail containing PMA and ionomycin (eBioscience) in RPMI with 10% fetal calf serum (Gemini). After 15 min, brefeldin A (eBioscience) was added. The cells were incubated at 37 °C 5% CO 2 for an additional 2 h. The cells were then collected and stained for intracellular cytokines following the protocol described above. Data are shown in Supplementary Fig. 10 .
Statistics.
Results are shown as mean with 95% confidence intervals. The statistics tests used were t test and Kolmogorov-Smirnov test, unless otherwise stated, as described with one-sided or two-sided in the figure legends. Benjamini-Hochberg FDR < 0.01 and fold change >2 were considered to be statistically significant when appropriate.
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